What were Dr Lal Pathlabs Ltd's latest quarterly results?
Dr Lal Pathlabs Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: -15.4% (inflecting downward)
- Revenue Growth YoY: +16.6%
- Operating Margin: 27.0% (stable)
Dr Lal Pathlabs Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +17.8%Average6w Streak
In , Dr Lal Pathlabs Ltd (Diagnostics) is outperforming Nifty 500 with +17.8% relative strength. Fundamentals: Average. On a 6-week streak.
Dr Lal Pathlabs Ltd Key Facts
- PE Ratio
- 53.7x
- Market Cap
- ₹28,317 Cr
- PAT Growth YoY
- -15%
- Revenue Growth YoY
- +17%
- OPM
- 27.0%
- RS vs Nifty 500
- +17.8%
PE: Near TroughWatch Value
What's Happening
💪Debt reduced 22% YoY — balance sheet strengthening
👔Promoter stake down 0.7% this quarter
🌐FII stake decreased 5.0% this quarter
🏛️DII accumulation — stake up 5.6%
💰Trading 60% above estimated fair value — significant premium
Key Numbers
PAT Growth YoY
-15%
Inflection Down
Revenue YoY
+17%
Stable
Operating Margin
27.0%
-100 bps YoY
PE Ratio
53.7
Current Price
₹1,689
Dividend Yield
0.83%
Fundamental Score
42/100
Average
3Y PAT CAGR
+28%
Market Cap
28.3K Cr
Valuation
Significantly Overvalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
How Fast Is Dr Lal Pathlabs Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +17% | +11% | Stable |
| PAT (Net Profit) | -15% | +28% | Inflection Down |
| OPM | 27.0% | -100 bps | Stable |
Other Top Diagnostics Stocks Beating Nifty 500
Frequently Asked Questions: Dr Lal Pathlabs Ltd
Based on publicly available financial data. This is educational research, not investment advice.
Is Dr Lal Pathlabs Ltd's profit growing or declining?
Dr Lal Pathlabs Ltd's profit is declining with an inflecting downward trend.
- PAT Growth YoY: -15.4% (latest quarter)
- PAT Growth QoQ: +45.1% (sequential)
- 3-Year PAT CAGR: +28.4%
- Trend: Inflecting downward — consistent growth pattern
What is Dr Lal Pathlabs Ltd's revenue growth trend?
Dr Lal Pathlabs Ltd's revenue growth trend is stable.
- Revenue Growth YoY: +16.6%
- Revenue Growth QoQ: +6.5% (sequential)
- 3-Year Revenue CAGR: +11.1%
How is Dr Lal Pathlabs Ltd's operating margin trending?
Dr Lal Pathlabs Ltd's operating margin is stable.
- Current OPM: 27.0%
- OPM Change YoY: -1.0% basis points
- OPM Change QoQ: 0.0% basis points
What is Dr Lal Pathlabs Ltd's 3-year profit and revenue CAGR?
Dr Lal Pathlabs Ltd's long-term compounding rates
- 3-Year Profit CAGR: +28.4%
- 3-Year Revenue CAGR: +11.1%
Is Dr Lal Pathlabs Ltd's growth accelerating or decelerating?
Dr Lal Pathlabs Ltd's earnings growth is inflecting downward with mixed signals on a sequential basis.
- YoY Acceleration: -8.3% bps
- Sequential Acceleration: +85.2% bps
What is Dr Lal Pathlabs Ltd's trailing twelve month (TTM) performance?
Dr Lal Pathlabs Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹509 Cr
- TTM PAT Growth: +3.3% YoY
- TTM Revenue: ₹3,000 Cr
- TTM Revenue Growth: +12.3% YoY
- TTM Operating Margin: 28.5%
Is Dr Lal Pathlabs Ltd overvalued or undervalued?
Dr Lal Pathlabs Ltd appears significantly overvalued based on our fair value analysis.
- Valuation Signal: Significantly Overvalued
- Current PE: 53.7x
- Price-to-Book: 11.3x
What is Dr Lal Pathlabs Ltd's current PE ratio?
Dr Lal Pathlabs Ltd's current PE ratio is 53.7x.
- Current PE: 53.7x
- Market Cap: 28.3K Cr
- Dividend Yield: 0.83%
How does Dr Lal Pathlabs Ltd's valuation compare to its history?
Dr Lal Pathlabs Ltd's current PE is 53.7x.
- Current PE: 53.7x
- Valuation Assessment: Significantly Overvalued
What is Dr Lal Pathlabs Ltd's price-to-book ratio?
Dr Lal Pathlabs Ltd's price-to-book ratio is 11.3x.
- Price-to-Book (P/B): 11.3x
- Book Value per Share: ₹150
- Current Price: ₹1689
Is Dr Lal Pathlabs Ltd a fundamentally strong company?
Dr Lal Pathlabs Ltd is rated Average with a fundamental score of 41.86/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +16.6% (10% weight)
- PAT Growth YoY: -15.4% (10% weight)
- PAT Growth QoQ: +45.1% (10% weight)
- Margins stable (10% weight)
Is Dr Lal Pathlabs Ltd debt free?
Dr Lal Pathlabs Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹199 Cr
What is Dr Lal Pathlabs Ltd's return on equity (ROE) and ROCE?
Dr Lal Pathlabs Ltd's return ratios over recent years
- FY2024: ROCE 25.0%
- FY2025: ROCE 29.0%
- FY2026: ROCE 28.0%
Is Dr Lal Pathlabs Ltd's cash flow positive?
Dr Lal Pathlabs Ltd's operating cash flow is positive (FY2026).
- Cash from Operations (CFO): ₹636 Cr
- Free Cash Flow (FCF): ₹214 Cr
- CFO/PAT Ratio: 125% (strong cash conversion)
What is Dr Lal Pathlabs Ltd's dividend yield?
Dr Lal Pathlabs Ltd's current dividend yield is 0.83%.
- Dividend Yield: 0.83%
- Current Price: ₹1689
Who holds Dr Lal Pathlabs Ltd shares — promoters, FII, DII?
Dr Lal Pathlabs Ltd's shareholding pattern (Mar 2026)
- Promoters: 53.2%
- FII (Foreign): 17.2%
- DII (Domestic): 21.4%
- Public: 7.9%
Is promoter holding increasing or decreasing in Dr Lal Pathlabs Ltd?
Dr Lal Pathlabs Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 53.2% (Mar 2026)
- Previous Quarter: 53.2% (Dec 2025)
- Change: 0.00% (stable)
How long has Dr Lal Pathlabs Ltd been outperforming Nifty 500?
Dr Lal Pathlabs Ltd has been outperforming Nifty 500 for 6 consecutive weeks, indicating building momentum.
Is Dr Lal Pathlabs Ltd a new momentum entry or an established outperformer?
Dr Lal Pathlabs Ltd is an established outperformer with 6 weeks of consecutive Nifty 500 outperformance.
Is Dr Lal Pathlabs Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Dr Lal Pathlabs Ltd may be worth studying
- Cash flow is positive — CFO ₹636 Cr
What is the investment thesis for Dr Lal Pathlabs Ltd?
Dr Lal Pathlabs Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +16.6% YoY
Risk Factors (Bear Case)
- Appears significantly overvalued
What is the future outlook for Dr Lal Pathlabs Ltd?
Dr Lal Pathlabs Ltd's forward outlook based on current data signals
- Earnings Trend: inflecting downward
- Revenue Trend: stable
- Margin Trend: stable
- Valuation: Significantly Overvalued
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.